Is Sagimet Biosciences Inc. (SGMT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 86.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 86.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 94.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 86.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 94.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -38.2% | |
| Return on Assets (ROA) | -25.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$46M |
| Free Cash Flow | -$46M |
| Total Debt | $78,000 |
| Debt-to-Equity | 0.1 |
| Current Ratio | 22.8 |
| Total Assets | $116M |
Price & Trading
| Last Close | $5.11 |
| 50-Day MA | $5.54 |
| 200-Day MA | $7.07 |
| Avg Volume | 558K |
| Beta | 3.4 |
|
52-Week Range
$1.73
| |
About Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sagimet Biosciences Inc. (SGMT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sagimet Biosciences Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sagimet Biosciences Inc.'s debt ratio?
Sagimet Biosciences Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Sagimet Biosciences Inc.'s key financial metrics?
Sagimet Biosciences Inc. has a market capitalization of $159M. Return on equity stands at -38.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.